A case report on variegate porphyria after etonogestrel placement

Arianna Strome, BS,a Spencer D. Hawkins, MD,b Yuan Yu Huang, MD,c and Yolanda R. Helfrich, MDd
Ann Arbor, Michigan and West Greenwich, Rhode Island

Key words: etonogestrel implant; porphyria; PPOX; variegate porphyria.

INTRODUCTION
Variegate porphyria (VP) is a rare disorder of heme synthesis caused by an autosomal dominant trait, partial deficiency in the protoporphyrinogen oxidase (PPOX) gene.1 It is characterized by acute attacks of neurovisceral symptoms—behavioral changes and abdominal pain—as well as cutaneous photosensitivity manifesting as skin fragility and blistering.2 Women are more likely to be symptomatic; skin symptoms typically develop in the second decade of life.1 Pertinently, many patients remain asymptomatic throughout their lives, while some patients present with either neurovisceral symptoms, photosensitivity, or both.2 It has a worldwide distribution but has an especially high frequency in South Africa.1 We report a teenage woman who presented with cutaneous VP after etonogestrel implant (Nexplanon) placement—a progestin-only contraceptive.

CASE REPORT
An 18-year-old woman, with a nonsignificant past medical history, presented with multiple erythematous, crusted, eroded papules on the dorsal aspects of the hands, as well as several lesions on the face. The lesions were painful, pruritic, nonhemorrhagic, and had been present for 1 month. The rash was initially thought to be consistent with impetigo, and she was prescribed mupirocin ointment to apply to affected regions. Over the ensuing month, existing lesions partially improved, but did not resolve; she developed new lesions on the face and crusting of the eyelids.

At a subsequent visit 1 month later, she continued to have round macules on the dorsal aspects of the hands and involvement of the nasal bridge (Fig 1). Based on the persistence of symptoms, the differential diagnosis was expanded to include porphyria and pseudoporphyria. Triggers were explored, and it was noted that she had an etonogestrel implant placed 4 months prior to presentation. This was the first time the patient had been on hormonal birth

Fig 1. On initial presentation, the patient demonstrated bilateral painful and pruritic erythematous crusted and eroded papules, ultimately found to be consistent with a cutaneous variegate porphyria flare.

From the Department of Pathologyc and Department of Dermatology,d University of Michigan Medical School, Ann Arbor; and Advanced Dermatology & Cosmetic Surgery, East Greenwich.b

Acknowledgments
None.

Funding sources: None.

IRB approval status: Not applicable.

Correspondence to: Yolanda R. Helfrich, MD, Associate Professor, Department of Dermatology, University of Michigan, 1910 Taubman Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109. E-mail: yolanda@med.umich.edu.

JAAD Case Reports 2022;22:104-6.
2352-5126 © 2022 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.jdcr.2022.02.024
control; it was implanted several weeks prior to the onset of symptoms.

Punch biopsies of 2 lesions on the dorsal aspect of the hand demonstrated largely normal acral-site epidermis with superficial dermal fibrosis, reactive angioplasia, scattered foci of microhemorrhage and angioplasia were observed (Hematoxylin-eosin stain; original magnification: ×100).

**Table I.** The patient’s laboratory test values that are consistent with variegate porphyria. Erythrocyte porphobilinogen deaminase activity was normal at 7.7 nmol/L/sec (reference value, ≥7.0 nmol/L/sec), and erythrocyte aminolevulinic acid dehydratase activity was normal at 4.9 nmol/L/sec (reference value, ≥4.0 nmol/L/sec)

| Urinary porphyrins          | Reference value | Case values |
|-----------------------------|----------------|-------------|
| Porphobilinogen             | ≤2.2 mcmol/24h | 69.3*       |
| Coproporphyrin (tetra)      | ≤168 nmol/24h  | 1260*       |
| Pentacarboxylporphyrins     | ≤10 nmol/24h   | 134*        |
| Hexacarboxylporphyrins      | ≤8 nmol/24h    | 29*         |
| Heptacarboxylporphyrins     | ≤9 nmol/24h    | 21*         |
| Uroporphyrin (octa)         | ≤30 nmol/24h   | 61*         |

| Fecal porphyrins            | Reference value | Case values |
|-----------------------------|----------------|-------------|
| Coproporphyrin I and III   | <500 and <400 mcg/24h, respectively | 1611* + 7675*, respectively |
| Protoporphyrin III/I ratio  | <1.2           | 4.76*       |
| Uroporphyrin I and III     | <1200 mcg/24h  | 14134*      |
| Coproporphyrin III/I ratio | <200 mcg/24h   | 1076*       |
| Isoproporphyrin             | <30 mcg/24h    | 32*         |
| Pentacarboxyl I and III    | <20 mcg/24h    | 41* + 92*, respectively |
| Isoheptacarboxyl            | <80 mcg/24h    | 166*        |
| Uroporphyrin I and III     | <120 and <50 mcg/24h, respectively | 32 + 8, respectively |
| Heptacarboxyl I and III    | <40 mcg/24h    | 2 + <1, respectively |
| Hexacarboxyl I and III     | <10 mcg/24h    | 3 + 5, respectively |

| Plasma porphyrins           | Reference value | Case values |
|-----------------------------|----------------|-------------|
| Uroporphyrin                | ≤1.0 mcg/dL    | ≤1.0        |
| Heptacarboxylporphyrins     | ≤1.0 mcg/dL    | ≤1.0        |
| Hexacarboxylporphyrins      | ≤1.0 mcg/dL    | ≤1.0        |
| Pentacarboxylporphyrins     | ≤1.0 mcg/dL    | ≤1.0        |
| Coproporphyrin              | ≤1.0 mcg/dL    | ≤1.0        |
| Protoporphyrin              | ≤1.0 mcg/dL    | 1.9*        |

*Elevated value.

**Fig 2.** A, Low-power view of the biopsy revealed normal epidermis with superficial dermal fibrosis. There was also a sparse superficial dermal perivascular lymphocytic infiltrate (Hematoxylin-eosin stain; original magnification: ×40). B, On higher-power view, scattered foci of microhemorrhage and angioplasia were observed (Hematoxylin-eosin stain; original magnification: ×100).
Additionally, weak linear IgG deposition was observed along the dermoepidermal junction. Direct immunofluorescence results were compatible with a porphyria immune deposition pattern. In combination, the histologic features were consistent with reparative changes in the setting of porphyria. Laboratory values confirming the diagnosis of VP are shown in Table I. Genetic testing with the Invitae Comprehensive Porphyrias Panel showed a heterozygous variant of uncertain significance in the PPOX gene (variant c.23T>C [p.Leu8Pro]).

She denied any acute porphyria symptoms, such as abdominal pain, neuropathy, nausea, or confusion. While de novo variants are very rare, she has no known family history of porphyria and denies South African ancestry; she has Russian Jewish ancestry. Due to the timeline of her cutaneous flare several weeks after etonogestrel implant placement, this was thought to be the trigger for her symptoms. She had the etonogestrel implant removed; over the ensuing month, she reported substantial improvement in her cutaneous symptoms, with minimal crusting and a decrease in size of lesions. She also used topical azelaic acid 10% in a cream vehicle with improvement in postinflammatory hyperpigmentation.

**DISCUSSION**

VP is a rare autosomal dominant disorder of the seventh step of heme synthesis caused by a mutation in the PPOX gene. Heme precursors build up in the liver, causing hepatic porphyria. There are 2 manifestations of disease: Acute neurovisceral attacks and cutaneous photosensitivity. Acute symptoms are characterized by behavioral changes, neuropathy, and abdominal pain. Skin symptoms often occur independently of neurovisceral attacks and are caused by a buildup of the PPOX substrate—protoporphyrinogen—in the skin, causing fragility and blistering in sun-exposed areas. It is diagnosed by plasma fluorescence with an emission peak at 626 nm. Patients have elevated fecal protoporphyrins and coproporphyrins, as well as elevated urine delta-aminolevulinic acid, porphobilinogen, and coproporphyrins and uroporphyrins.

It has been shown that stress, infection, fasting, and drugs that induce cytochrome P-450 enzymes trigger VP exacerbations. Additionally, sex steroids—particularly progesterone—are inducers of heme synthesis and can provoke porphyria symptoms in women. Cyclical acute porphyria attacks have been reported during the luteal phase of the menstrual cycle, when progesterone is particularly elevated. To the authors’ knowledge, this is the first report of cutaneous VP triggered by progesterone-only Nexplanon implantation.

**Conflicts of interest**

None disclosed.

**REFERENCES**

1. Di Pierro E, Ventura P, Brancaleoni V, et al. Clinical, biochemical and genetic characteristics of variegate porphyria in Italy. *Cell Mol Biol (Noisy-le-grand).* 2009;55(2):79-88.
2. Kauppinen R. Porphyrias. *Lancet.* 2005;365(9455):241-252. https://doi.org/10.1016/S0140-6736(05)17744-7
3. Barbaro M, Kotajärvi M, Harper P, Floderus Y. Partial protoporphyrinogen oxidase (PPOX) gene deletions, due to different Alu-mediated mechanisms, identified by MLPA analysis in patients with variegate porphyria. *Orphanet J Rare Dis.* 2013;8:13. https://doi.org/10.1186/1750-1172-8-13
4. Hift RJ, Peters TJ, Meissner PN. A review of the clinical presentation, natural history and inheritance of variegate porphyria: its implausibility as the source of the ‘Royal Malady’. *J Clin Pathol.* 2012;65(3):200-205. https://doi.org/10.1136/jclinpath-2011-200276
5. Innala E, Bäckström T, Bixo M, Andersson C. Evaluation of gonadotropin-releasing hormone agonist treatment for prevention of menstrual-related attacks in acute porphyria. *Acta Obstet Gynecol Scand.* 2010;89(1):95-100. https://doi.org/10.3109/00016340903390729